Teleflex Inc TFX
We take great care to ensure that the data presented and summarized in this overview for TELEFLEX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TFX
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.91MShares$1.05 Billion0.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.59MShares$996 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X05.38MShares$958 Million0.71% of portfolio
-
Black Rock Inc. New York, NY3.88MShares$691 Million0.02% of portfolio
-
Morgan Stanley New York, NY3.24MShares$577 Million0.06% of portfolio
-
State Street Corp Boston, MA2.06MShares$366 Million0.02% of portfolio
-
Atlanta Capital Management CO L L C Atlanta, GA1.44MShares$257 Million1.29% of portfolio
-
Geode Capital Management, LLC Boston, MA1.13MShares$201 Million0.02% of portfolio
-
Cooke & Bieler LP883KShares$157 Million2.23% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny744KShares$133 Million0.09% of portfolio
Latest Institutional Activity in TFX
Top Purchases
Top Sells
About TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Insider Transactions at TFX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 24
2024
|
John Deren Corp. VP & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
16
-0.8%
|
$3,872
$242.41 P/Share
|
Aug 16
2024
|
Stuart A Randle Director |
SELL
Open market or private sale
|
Direct |
2,674
-32.73%
|
$636,412
$238.93 P/Share
|
Aug 16
2024
|
Stuart A Randle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,674
+24.66%
|
$323,554
$121.0 P/Share
|
Jun 18
2024
|
James Winters Corp VP, Mfg and Supply |
BUY
Grant, award, or other acquisition
|
Direct |
243
+6.26%
|
-
|
May 07
2024
|
Andrew A Krakauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+11.23%
|
-
|
May 07
2024
|
Gretchen R Haggerty Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+12.01%
|
-
|
May 07
2024
|
Candace H Duncan Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+12.12%
|
-
|
May 07
2024
|
Stephen K. M.D. Klasko Director |
BUY
Grant, award, or other acquisition
|
Direct |
838
+10.51%
|
-
|
May 07
2024
|
Stuart A Randle Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+10.56%
|
-
|
May 07
2024
|
Jaewon Ryu Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+35.56%
|
-
|
May 07
2024
|
Neena M Patil Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+29.18%
|
-
|
May 07
2024
|
John C Heinmiller Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+17.2%
|
-
|
Mar 05
2024
|
Cameron P Hicks Corp. VP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
7,401
-42.41%
|
$1,665,225
$225.0 P/Share
|
Mar 05
2024
|
Cameron P Hicks Corp. VP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,401
+19.42%
|
$976,932
$132.89 P/Share
|
Mar 02
2024
|
John Deren Corp. VP & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-6.45%
|
$30,551
$223.0 P/Share
|
Mar 02
2024
|
Daniel V. Logue CVP, General Counsel & Secty |
SELL
Payment of exercise price or tax liability
|
Direct |
149
-1.16%
|
$33,227
$223.0 P/Share
|
Mar 02
2024
|
Liam Kelly Chairman, President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,840
-6.38%
|
$410,320
$223.0 P/Share
|
Mar 02
2024
|
Cameron P Hicks Corp. VP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-2.1%
|
$48,600
$225.0 P/Share
|
Mar 02
2024
|
James Winters Corp VP, Mfg and Supply |
SELL
Payment of exercise price or tax liability
|
Direct |
305
-8.24%
|
$68,015
$223.0 P/Share
|
Mar 02
2024
|
Jay White CVP & Pres, Global Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
239
-3.86%
|
$53,297
$223.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 23.5K shares |
---|---|
Exercise of conversion of derivative security | 37.9K shares |
Open market or private sale | 36.3K shares |
---|---|
Payment of exercise price or tax liability | 4.46K shares |